Centocor takes up UK Medical Research Council's respiratory immunotherapy
This article was originally published in Scrip
The UK Medical Research Counciland MRC Technology have licensed rights to an immunotherapy with potential in respiratory disease to CentocorOrtho Biotech (Johnson & Johnson). Centocor has exclusively licensed patents to the technology and will pay development milestone and royalties on any net sales that may result.
You may also be interested in...
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.